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Background: The purpose of this study was to characterize intraocular pressure (IOP) 
  reduction throughout the day with travoprost ophthalmic solution 0.004% dosed once daily 
in the evening.
Methods: The results of seven published, randomized clinical trials including at least one 
arm in which travoprost 0.004% was dosed once daily in the evening were integrated. Means 
(and standard deviations) of mean baseline and on-treatment IOP, as well as mean IOP reduc-
tion and mean percent IOP reduction at 0800, 1000, and 1600 hours at weeks 2 and 12 were 
calculated.
Results: From a mean baseline IOP ranging from 25.0 to 27.2 mmHg, mean IOP on treat-
ment ranged from 17.4 to 18.8 mmHg across all visits and time points. Mean IOP reductions 
from baseline ranged from 7.6 to 8.4 mmHg across visits and time points, representing a mean 
IOP reduction of 30%. Results of the safety analysis were consistent with the results from the 
individual studies for travoprost ophthalmic solution 0.004%, with ocular hyperemia being the 
most common side effect.
Conclusion: Travoprost 0.004% dosed once daily in the evening provides sustained IOP reduc-
tion throughout the 24-hour dosing interval in subjects with ocular hypertension or open-angle 
glaucoma. No reduction of IOP-lowering efficacy was observed at the 1600-hour time point 
which approached the end of the dosing interval.
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Introduction
Intraocular pressure (IOP) is an important risk factor for the development and pro-
gression of glaucoma. In recent years, The Ocular Hypertension Treatment Trial has 
demonstrated that IOP reduction can prevent the development of glaucoma among 
individuals with ocular hypertension1,2 and can reduce the risk of glaucoma progression 
among subjects with both normal3–5 and elevated IOP.4 The impact of both short-term 
and long-term IOP variability on progression risk has also been explored, with many6–10 
(but not all)11,12 studies finding a positive relationship between greater IOP variability 
and higher rates of glaucomatous progression or development.
The possibility that IOP variability may be a risk factor for glaucoma progression 
has stimulated a growing interest in the clinical evaluation and characterization of 
  diurnal variability. A number of recent studies have challenged traditional thinking 
about IOP behavior. Historically, circadian IOP was believed to reach its peak values in 
the morning hours around the time of waking. These studies were typically conducted 
with subjects in the sitting position. When the physiologically more appropriate habitual 
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position was studied, with subjects sitting during daytime 
hours and supine at night, a different IOP pattern emerged 
in which IOP peaked at night during sleeping hours in both 
healthy13–17 and glaucomatous individuals.13,17 Additionally, 
diurnal IOP patterns may not be conserved from day to 
day,18,19 and IOP fluctuations in fellow-eye pairs may be less 
well correlated than previously believed.16,20–22
Despite this growing body of research suggesting that 
IOP variability may predict future glaucoma progression, 
routine evaluation of circadian IOP in clinical practice 
remains a significant clinical challenge. Unlike for blood 
pressure or blood glucose levels, there are no inexpensive, 
easy-to-use devices for home or self-assessment of IOP. IOP 
measurement remains an in-office assessment, rendering 
characterization of individual IOP variability both expensive 
and time-consuming. Adding to the challenge of clinical IOP 
variability is the observation that most subjects experience 
their peak IOP after typical office hours.13,17
In light of the realization that consistent IOP reduction 
throughout the 24-hour period is important in preventing 
glaucomatous progression, coupled with the difficulties 
of assessing 24-hour IOP in routine clinical practice, there 
remains a need for therapy that provides consistent IOP 
reduction throughout the dosing interval with minimal peak 
and trough variability.
Travoprost ophthalmic solution 0.004% is a prostaglandin 
analog available throughout the global marketplace and indi-
cated for IOP reduction in subjects with open-angle glaucoma 
or ocular hypertension. Travoprost ophthalmic solution has 
been formulated with a variety of preservatives. This paper 
reports the results of an integrated analysis of seven random-
ized clinical trials containing at least one travoprost 0.004% 
monotherapy arm,23–29 the goal of which is to characterize 
the consistency of IOP reduction throughout the travoprost 
dosing interval.
Materials and methods
This integrated analysis comprised data from seven peer-
reviewed, published, prospective randomized trials. Each 
study was conducted at multiple clinical centers throughout 
the world, and each was reviewed and approved by the appro-
priate ethics committees. Because this integrated analysis 
utilized study-level data rather than subject-level data, no 
individual data were accessed or analyzed, and no further 
ethics committee approval was required.
The seven studies included in this integrated analysis 
were selected based on shared characteristics. All but one 
were registration trials and each was conducted according 
to the rigorous and robust methodology required by the US 
Food and Drug Administration and other international drug 
approval bodies; the sole nonregistration trial was a duration 
of action study conducted to registration trial standards. 
Phase IV studies were excluded because the design of these 
trials differs from those of the registration trials (ie, sample 
size, endpoints, and inclusion and exclusion criteria). Six of 
the included studies were registration trials for travoprost 
preserved with either benzalkonium chloride (Travatan®, 
Alcon Laboratories, Fort Worth, TX) or sofZia® (Travatan Z®, 
Alcon); one was a registration trial for a travoprost-timolol 
fixed combination (DuoTrav®, Alcon) that included a travo-
prost monotherapy arm in a contribution of elements design. 
All seven studies utilized travoprost in strict accordance 
with its labeling, employed identical dosing regimens, and 
all had previously been published. Because of their shared 
purpose and design, the subjects enrolled in these studies 
met similar eligibility criteria and are thus a substantially 
homogenous population taken as a whole. Table 1 lists the 
key design characteristics of the seven studies included in 
this integrated analysis.
The primary objective of this study was to characterize 
the consistency of IOP reduction achieved with travoprost 
0.004% dosed once daily throughout the 24-hour dosing 
interval. The primary outcome of this descriptive analysis 
was the mean percent change from baseline in IOP at week 2 
and week 12 at 0800, 1000 and 1600 hours (0900, 1100, and 
1600 in European studies), which represent the latter half of 
the 24-hour dosing interval for travoprost. Not every study 
in the integrated analysis included IOP assessments at each 
of these visits and time points; as such, the sample size at 
each visit and time point was not constant.
For the mean and standard deviation, we exploited the 
fact that both of these parameters can be calculated for any 
collection of data using the sample size, the sum of the data 
values, and the sum of the squares of the data values. For 
a sample consisting of k values of the variable x, which we 
will denote as x1, x2, … xk, we have
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where T denotes the sum of the x values, easily obtained 
by multiplying the sample mean by the sample size. 
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Table 1 Key design features of the seven studies included in this integrated analysis
Reference n, Travoprost 0.004% arm(s) ITT/PP Study eye IOP criteria Visits and time points
Netland et al29 197/187 24–36 mmHg at 0800 and 21–36 mmHg  
at 1000 and 1600 on two separate visits
0800, 1000, and 1600 at baseline,   
week 2, and week 12
Gross et al27 52/52 Travoprost 
54/54 Travoprost with sofZia®
24–36 mmHg at 0800 0800 at baseline and week 2
Lewis et al28 341/339 Travoprost 
338/322 Travoprost with sofZia®
24–36 mmHg at 0800 and 21–36 mmHg  
at 1000 and 1600 on two separate visits
0800, 1000, and 1600 at baseline,   
week 2, and week 12
Goldberg et al26 197/176 24–36 mmHg at 0900 and 21–36 mmHg  
at 1100 and 1600 on two separate visits
0900, 1100, and 1600 at baseline,   
week 2, and week 12
Barnebey et al23 84/77 $26 mmHg at 0800 on two separate visits,  
$24 mmHg at 1000 on one visit, and  
$22 mmHg at 1600 on one visit
0800, 1000, and 1600 at baseline,   
week 2, and week 12
Fellman et al24 197/179 24–36 mmHg at 0800 on 2 separate visits 0800, 1000 and 1600 at baseline,  
week 2 and week 12
Gandolfi et al25 185/177 Travoprost 
185/176 Travoprost with sofZia®
24–36 mmHg at 0900 and 21–36 at 1100  
and 1600 on two separate visits
0900, 1100 and 1600 at baseline,  
week 2 and week 12
Abbreviations: iTT, intent to treat; PP, per protocol; iOP, intraocular pressure.
For each study that contributed data to the integrated sum-
mary,   working backwards from the sample size, mean, and 
standard deviation that had been provided, the formulae above 
were applied to calculate the sum of the data values and the 
sum of the squares of the data values for the study. These 
sums (and the sample sizes) were then added across all of 
the contributing studies in order to obtain the overall sample 
size, the sum of the combined data, and the sum of squares of 
the combined data. Applying the formulae above once again, 
the mean and standard deviation of the combined data were 
then obtained. Both the intent-to-treat and per protocol data 
sets were analyzed, and the results of both these analyses 
were similar. The per protocol data set is presented in this 
paper, because this integrated analysis is not a comparative 
study, and the per protocol data set is limited to those who 
were both randomized to and received travoprost 0.004% as 
study medication, and is therefore a more robust estimate of 
the efficacy of travoprost.
Results
Subject disposition and demographics
The integrated analysis consisted of data collected from a 
total of 1669 subjects, all of whom were included in the safety 
analysis. The intent-to-treat analysis included 1645 subjects 
who attended at least one on-treatment assessment. The per 
protocol analysis included 1563 subjects. Common reasons 
that subjects were excluded from the per protocol data set 
included failure to achieve required washout IOP level, use of 
excluded concomitant medications, nonadherence with study 
medication dosing, and other violations of eligibility criteria. 
Demographic and baseline characteristics of the integrated 
per protocol study population are given in Table 2.
Source data
The mean (± standard deviation) IOP at each visit and time 
point in the travoprost arms of each of the seven studies 
included in this integrated analysis are given in Table 3. These 
are the values from the per protocol analyses and therefore 
may differ from values in the published study reports which 
used intent-to-treat analyses in keeping with the design and 
statistical goals of those studies.
Consistency of iOP reduction
The baseline IOP and mean IOP, mean IOP reduction, 
and mean percent IOP reduction at each on-treatment 
visit and time point in the per protocol data set are given 
in Table 4. From mean baseline IOP ranging from 25.0 to 
27.2 mmHg, mean IOP on treatment ranged from 17.4 to 
18.8 mmHg across all visits and time points. Mean IOP 
Table 2 Demographics and baseline characteristics of subjects in 
the per protocol data set (n = 1563) of the integrated analysis
Age (years), mean (standard deviation) 63.1 ± 11.3
Gender, n (%)
  Male 719 (46.0)
  Female 844 (54.0)
Ethnicity, n (%)
  Caucasian 1130 (72.3)
  Black 247 (15.8)
  Hispanic 89 (5.7)
  Asian 41 (2.6)
  Other 56 (3.6)
Diagnosis, n (%)
  Open-angle glaucoma 962 (61.5)
  Ocular hypertension 549 (35.1)
  Pigmentary glaucoma 27 (1.7)
  Pseudoexfoliation glaucoma 25 (1.6)
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Table 3 Mean (± standard deviation) intraocular pressure (mmHg) at each visit and time point in the travoprost arms of the seven 
studies included in this integrated analysis (per protocol data set)
Reference Baseline Week 2 Week 12
0800 1000 1600 0800 1000 1600 0800 1000 1600
Netland et al29 26.8 (2.6) 25.2 (2.8) 24.6 (2.8) 18.8 (3.6) 17.52 (3.5) 17.3 (3.0) 18.7 (3.3) 17.3 (3.7) 17.6 (3.1)
Gross et al27
  Travoprost 27.1 (2.9) – – 18.5 (4.0) – – – – –
    Travoprost 
with sofZia®
26.9 (3.2) – – 18.7 (4.2) – – – – –
Lewis et al28
  Travoprost 27.2 (2.7) 25.6 (2.9) 24.9 (2.9) 18.8 (3.5) 17.9 (3.6) 17.5 (3.5) 18.8 (3.6) 17.7 (3.3) 17.2 (3.1)
    Travoprost 
with sofZia®
27.0 (2.3) 25.5 (2.7) 24.8 (2.7) 18.5 (2.9) 17.7 (3.3) 17.3 (3.1) 18.7 (3.5) 17.7 (3.2) 17.3 (3.2)
Goldberg et al26 27.4 (2.8) 26.5 (2.9) 25.6 (3.0) 18.9 (3.4) 17.9 (3.3) 17.4 (3.3) 18.5 (3.4) 17.6 (3.1) 16.8 (2.9)
Barnebey et al23 29.8 (2.7) 28.2 (3.1) 26.9 (3.5) 20.6 (3.9) 19.0 (3.8) 18.6 (3.6) 20.6 (3.7) 19.2 (3.2) 18.7 (3.2)
Fellman et al24 27.3 (3.0) 25.7 (3.4) 25.1 (3.0) 19.3 (3.7) 18.1 (3.4) 17.6 (3.2) 19.7 (3.9) 18.5 (3.8) 18.0 (3.3)
Gandolfi et al25 26.9 (2.6) 25.6 (2.9) 24.8 (2.8) 18.1 (3.5) 17.8 (3.5) 17.1 (3.2) 18.0 (3.5) 17.4 (3.4) 17.0 (3.7)
Note: All studies evaluated travoprost (preserved with benzalkonium chloride) unless otherwise stated.
Table 4 Mean iOP at baseline and mean iOP, mean iOP reduction, and percent mean iOP reduction at each visit and time point in the 
per protocol data set of the integrated analysis
Baseline Week 2 Week 12
0800 1000 1600 0800 1000 1600 0800 1000 1600
iOP, mmHg
  Mean 27.2 25.8 25.0 18.8 17.9 17.4 18.8 17.8 17.4
  SD 2.7 3.0 2.9 3.5 3.5 3.3 3.6 3.4 3.2
 n 1563 1456 1457 1539 1436 1435 1376 1375 1375
iOP reduction, mmHg
  Mean – – – -8.4 -7.9 -7.6 -8.5 -7.9 -7.6
  SD – – – 3.3 3.5 3.4 3.3 3.5 3.3
 n – – – 1539 1463 1435 1376 1375 1375
Percent iOP reduction, %
  Mean – – – -30.8 -30.4 -30.0 -30.9 -30.5 -30.1
  SD – – – 11.3 12.3 11.9 11.5 12.0 11.8
 n – – – 1539 1436 1435 1376 1375 1375
Abbreviations: iOP, intraocular pressure; SD, standard deviation.
reductions from baseline ranged from 7.6 to 8.4 mmHg 
across visits and time points, with less than a 1 mmHg dif-
ference between 0800 and 1600 time points at both weeks 2 
and 12. Mean percent IOP reductions were remarkably 
consistent throughout the day. Mean IOP was lowered by 
at least 30% at every visit and time point, including the 
1600-hour time point, 20 hours into the travoprost dosing 
interval (Figure 1).
Safety
Among the 1669 subjects in this integrated analysis, 
  travoprost was generally well tolerated, and most adverse 
events were mild to moderate in severity and required 
no intervention. The discontinuation rate due to all 
adverse events was 3.2% (53 of 1666 subjects for whom 
  discontinuation data were available). The adverse events 
seen in 1% or more of subjects are given in Table 5. Ocular 
hyperemia was the most common adverse event. In three of 
the studies, ocular hyperemia was identified as an adverse 
event if the study physician judged that it had increased 
by one or more points on a four-point (0–3) scale; in the 
remaining four studies, ocular hyperemia was identified 
as an adverse event if the subject reported it. The rate 
of physician-reported ocular hyperemia (increase of one 
unit on a four-point scale) was 38.8% (232/598 subjects), 
while the rate of subject-reported ocular hyperemia was 
8.5% (91/1071 subjects). Other common adverse events 
included ocular itching, discomfort, pain, dry eye, foreign 
body sensation, and keratitis, each of which occurred at an 
incidence between 1%–5%.
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Figure 1 Mean percent intraocular pressure reduction by visit and time point.
Table 5 Adverse events occurring at a rate of 1% or greater in 
the integrated analysis (n = 1669 subjects with safety data)
n (%)
Ocular hyperemia, physician-reported (n = 598/1669) 232 (38.8)
Ocular hyperemia, subject-reported (n = 1071/1669) 91 (8.5)
Ocular pruritus 69 (4.1)
Ocular discomfort 51 (3.1)
Ocular pain 35 (2.1)
Dry eye 33 (2.0)
Foreign body sensation 33 (2.0)
Keratitis 23 (1.4)
Discussion
The current study demonstrates that travoprost ophthalmic 
solution 0.004% provides a sustained 30% IOP reduction. 
In this integrated analysis, travoprost exhibited no reduction 
of effect even in the latter portion of the 24-hour period. 
These results are consistent with the individual results of the 
included studies but provide a more robust estimate of the 
circadian IOP-lowering profile of travoprost in a sample of 
over 1500 subjects.
Consistent reduction of IOP throughout the 24-hour 
period is emerging as an important consideration in the 
management of glaucoma. An early study by Asrani et al 
brought attention to the role of IOP fluctuation in glaucoma 
progression.6 In that study, glaucoma subjects who had 
undergone diurnal IOP assessment several years previously, 
using a home tonometer initially designed for research 
applications, were assessed retrospectively for subsequent 
visual field progression. Subjects in the upper 25th percen-
tile of diurnal IOP range were significantly more likely to 
experience glaucomatous progression compared with those 
in the lower 25th percentile, independent of mean IOP. More 
recently, a multicenter chart review found that the risk of 
progression increased by approximately 4–5-fold with each 
one unit increase in the standard deviation of intervisit IOP.7 
While essentially no prospective studies have been designed 
specifically to evaluate the significance of diurnal variability 
on glaucoma progression, its importance can be inferred from 
analyses of many recent clinical trials. Post hoc analyses 
of cohorts of patients from both the Advanced Glaucoma 
Intervention Study8,9 and the Collaborative Initial Glaucoma 
Treatment Study10 data sets found associations between 
IOP variability and the risk of visual field progression. In 
contrast, the Early Manifest Glaucoma Study and Malmo 
Ocular Hypertension Study data sets did not confirm this 
association.11,12 One potential explanation for these dispa-
rate findings is that IOP variability may be less important in 
early-stage glaucoma compared with later-stage glaucoma.30 
Given these reports, and despite the lack of appropriately 
designed and adequately powered studies directly exploring 
this topic, a preponderance of evidence to date suggests that 
IOP variability is relevant in the discussion of risk factors 
for glaucoma progression.
Our understanding of both diurnal IOP variability and 
long-term IOP fluctuation is limited by the paucity of studies 
on these topics, which in turn is attributable to the lack of 
home tonometry and the expense of collecting the many IOP 
measurements necessary to characterize IOP behavior over 
time. Peak IOP has recently been identified as an important 
IOP parameter associated with disease progression.31 IOP 
peaks at night when subjects are sleeping supine,13–17 mak-
ing it impractical to determine peak IOP in routine clinical 
practice. Moreover, peak IOP may not occur at the same 
time on each day, because IOP patterns in both healthy and 
glaucomatous individuals are not highly conserved from day 
to day.18,19 Thus, assessing the efficacy of drug therapy in 
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reducing an individual’s peak IOP is not currently feasible in 
clinical practice. In light of this important limitation, a drug 
that consistently lowers IOP at all time points throughout 
the dosing interval would have value in reducing both the 
diurnal IOP variability and the long-term fluctuation of IOP 
in subjects with open-angle glaucoma or ocular hypertension. 
The current analysis demonstrates that travoprost 0.004% 
dosed once daily in the evening provides a sustained mean 
IOP reduction of 30% throughout the day. Furthermore, this 
efficacy was consistent, being comparable at both week 2 and 
week 12 in the integrated analysis of seven clinical trials.
The clinical significance of a 30% IOP reduction is 
based on observations from major clinical trials. In the 
Ocular Hypertension Treatment Study, a 20% IOP reduc-
tion significantly reduced but did not eliminate the rate 
of conversion from ocular hypertension to open-angle 
  glaucoma.1 Similarly, an average 25% IOP reduction in 
the Early Manifest Glaucoma Trial significantly reduced 
but did not eliminate progression of manifest glaucoma.4 
In contrast, subjects in both the medically and surgically 
treated arms of the   Collaborative Initial Glaucoma Treat-
ment Study   demonstrated long-term stability of glaucoma, 
with mean IOP reductions of approximately 35% and 48%, 
respectively.32 These studies, taken together, suggest that the 
relationship between IOP reduction and glaucoma may take 
the form of a threshold effect; 25% reduction is not enough, 
and in excess of 35% may not be necessary for subjects with 
early or moderate open-angle glaucoma. We lack data on IOP 
reductions between 25%–35% to identify more precisely the 
optimal threshold IOP reduction.
The sustained 30% IOP reduction from baseline that 
can be achieved with travoprost monotherapy is a reason-
able therapeutic target for most subjects with open-angle 
glaucoma or ocular hypertension. Some subjects, such as 
those with higher IOP, more advanced disease, or high-risk 
factors such as pseudoexfoliation, may require greater IOP 
reductions to achieve disease stability.
This analysis is strengthened by its large sample size, 
which permits robust estimation of both the efficacy and 
safety profiles of travoprost. It is also strengthened by inclu-
sion of studies conducted to registration trial standards, thus 
ensuring that each study was adequately designed and pow-
ered and conducted under the strictest of protocols, each of 
which shared important methodological similarities such as 
eligibility criteria and IOP assessment. These key design fea-
tures assure the integrity of both the efficacy and safety data 
collected in each study. The analysis is limited by the lack 
of nocturnal IOP data, which are not a standard component 
of registration trials for IOP-lowering medications. The data 
in this analysis cover only half the dosing interval, but it is 
the latter half, which represents a worst-case scenario when 
presumably efficacy approaches a trough effect.
This integrated analysis, with its large sample size for a 
prostaglandin analog study, allows a fuller characterization 
of the safety profile of travoprost. The safety profile identi-
fied in this analysis was consistent with the results of the 
individual studies, with hyperemia being the most common 
adverse event.
In summary, this integrated analysis demonstrates that 
travoprost 0.004% dosed once daily in the evening provides 
sustained 30% mean IOP reduction throughout the day in 
subjects with ocular hypertension or open-angle glaucoma. 
No significant loss of IOP-lowering efficacy was observed 
at the 1600-hour time point, which approached the end of 
the dosing interval.
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